Article Extended Data Fig. 1 | Imaging mass cytometry of lymph nodes in patients with melanoma. ( a ) Breslow score (left) and tumour metastatic tumour burden (right) in the TDLNs of stage II (n = 10) or III (n = 11) patients with melanoma included in the IMC cohort, visualized as mean ± s.d. Patients were divided into those who remained disease free (‘DF’, RFS > 60–96 months) or developed distant disease recurrence (‘R’, RFS < 24–48 months) following surgery (5–6 patients per group). A Kruskal-Wallis test was performed to test for differences (all P > 0.05). ( b ) Signal-to-noise ratio (SNR; y axis) plotted against signal intensity ( x axis) for each individual marker in the IMC panel (calculated on a per cell basis). ( c ) CellProfiler cell mask images with nuclear staining (top; white signal) and the corresponding cell mask (bottom, in red). ( d ) Representative images of selected IMC markers for each anatomical location selected in the TDLN. Cell segmentation and annotation is shown on top. ( e ) Proportions of cells derived from the indicated sample groups. Patients with stage II or III melanoma were divided into DF/R groups (see above) and analysed per anatomical location in the TDLN. ( f ) Proportions of cells found per anatomical location across sample groups. ( g ) Patient IDs projected on the batch-corrected UMAP visualization of all cells detected in the IMC experiments. ( h ) Anatomical locations of isolated cells projected on batch- corrected UMAP visualization of all cells detected (IMC).